Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs

Autor: C. Ritleng, Eric Van Ganse, Marie-Sophie Schwalm, Laurent Laforest, T. Souchet, G. Desamericq, Philippe Le Jeunne, Philippe Moulin
Přispěvatelé: Health Service and Performance Research (HESPER), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon
Jazyk: angličtina
Rok vydání: 2009
Předmět:
Male
Prevalence
Fibrate
030204 cardiovascular system & hematology
Gastroenterology
Triglyceride
chemistry.chemical_compound
0302 clinical medicine
High-density lipoprotein
Risk Factors
Médecine générale
Epidemiology
030212 general & internal medicine
Triglycérides
Hypolipidemic Agents
Hypertriglyceridemia
HDL-Cholestérol
General Medicine
Middle Aged
3. Good health
Treatment Outcome
Cholesterol
Cardiovascular Diseases
Practice Guidelines as Topic
lipids (amino acids
peptides
and proteins)
Female
Cardiology and Cardiovascular Medicine
medicine.medical_specialty
Statin
HDL
medicine.drug_class
education
Risk Assessment
LDL
Statines
03 medical and health sciences
primary care
Internal medicine
medicine
Humans
Dyslipidemias
Aged
business.industry
Prevention
Cholesterol
HDL
nutritional and metabolic diseases
Cholesterol
LDL
medicine.disease
Endocrinology
Cross-Sectional Studies
chemistry
HDL-Cholesterol
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
business
Fibrates
Zdroj: Archives of cardiovascular diseases
Archives of cardiovascular diseases, Elsevier/French Society of Cardiology, 2009, 102 (1), pp.43--50. ⟨10.1016/j.acvd.2008.06.021⟩
ISSN: 1875-2136
Popis: International audience; AIM: To estimate the prevalence of triglyceride and/or high density lipoprotein cholesterol (HDL-C) disorders and their relationships with other cardiovascular risk factors among patients with dyslipidaemia on lipid-lowering therapy. METHODS: In this cross-sectional study in dyslipidaemic patients receiving lipid-lowering therapy, lipid disorders were defined as triglyceride greater than 1.5 g/L, HDL-C lesser than 0.4 g/L and low-density lipoprotein cholesterol (LDL-C) above the recommended concentration according to French guidelines. Based on these disorders, patients were classified into four groups: group 1, no lipid disorders; group 2, low HDL-C and/or high triglyceride concentration with normal LDL-C; group 3, isolated elevated LDL-C; and group 4, elevated LDL-C and low HDL-C and/or high triglyceride. Patients' cardiovascular risk levels were compared across groups. RESULTS: Among the 2727 patients (mean age 64.7 years, 46.7% women), 28% did not reach the target LDL-C concentration as defined by French guidelines. Prevalence rates of high triglyceride and low HDL-C were 27.2 and 10.3%, respectively. Over half (51.2%) of the patients were in group 1, 20.5% were in group 2, 16.2% in group 3 and 12.1% in group 4. Among patients meeting the target LDL-C, those with high triglyceride and/or low HDL-C exhibited a significantly higher number of risk factors (1.83 vs 1.68, p\\textless0.001). Smoking, diabetes and hypertension were associated separately with low HDL-C and/or high triglyceride (p=0.01, p\\textless0.0001, p=0.03, respectively). Conversely, these associations were not observed in patients who did not achieve the target LDL-C, with the exception of smoking (p\\textless0.0001). CONCLUSION: HDL-C and triglyceride disorders are relatively frequent among treated patients, particularly when cardiovascular risk level increased.
Databáze: OpenAIRE
Externí odkaz: